It's a labyrinth of policies, fine print, and frustrating hurdles
However, if you have been at maximum dose for 12 or more weeks without adequate response, or if side effects prevent further dose increases, switching to tirzepatide is a reasonable next step
in the treatment-policy estimand analysis the 14 mg oral-semaglutide group had mean A1C reductions from baseline of -1.3%, -1.2%, and -1.1% at 26, 52, and 78 weeks, respectively
Consistent data collection makes protocol adjustments more informed and outcomes more meaningful
doi: 10.3390/nu14122414 38 GomezJCLoridoJCAMartinezLG
The Peptide Unit Converter shows exact unit counts for any concentration and dose combination